Results 41 to 50 of about 22,486 (258)

Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease. [PDF]

, 2016
BACKGROUND: Priapism is unwanted painful penile erection that affects about 36% of boys and men with sickle cell disease (SCD) most of whom have sickle cell anemia. Clinically, priapism could be stuttering, minor, or major.
Adeyoju, Ayache, Ballas, Ballas, Baron, Betke, Charache, Eckman, Emond, Harms, Janes, Mantadakis, Okpala, Powars, Rackoff, Rogers, Seeler, Serjeant, Serjeant, Sharpsteen, Siegel, Talacki, Teixeira, US Department of Health and Human Services   +23 more
core   +2 more sources

System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe. [PDF]

, 2005
Low cost and effective drugs, such as magnesium sulphate, need to be included in initiatives to improve access to essential medicines in ...
Cliff, J, Daniels, K, Fernandes, B, Lewin, S, Mariano, A, Matinhure, S, Oxman, AD, Sevene, E, Woelk, G   +8 more
core   +2 more sources

Consideration of ethnic differences in approvals for anti‐HIV medicines in Japan: Evaluation based on pharmacokinetic studies and post‐marketing data

British Journal of Clinical Pharmacology, EarlyView.
More than 30 anti‐HIV drugs have been approved in Japan using data from dossiers submitted to the United States or European regulatory authorities since 1998. These drugs were approved with the same dosage and administration regimes as in the United States and Europe, using data from pivotal studies that rarely included any Japanese patients, whereas ...
Rumiko Shimazawa, Masayuki Ikeda
wiley   +1 more source

Parenteral hydralazine revisited

The Journal of Emergency Medicine, 1998
Historical aspects of the development and application of the vasodilator hydralazine are reviewed. The pharmacology, pharmacokinetics, metabolism, and mechanism of action are discussed, with emphasis on the parenteral use of this drug. It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its ...
Peter J. Papadakos, J. David Wallin, David R. Powers   +2 more
openaire   +3 more sources

Genotype-Guided Hydralazine Therapy [PDF]

American Journal of Nephrology, 2020
<b><i>Background:</i></b> Despite its approval in 1953, hydralazine hydrochloride continues to be used in the management of resistant hypertension, a condition frequently managed by nephrologists and other clinicians. Hydralazine hydrochloride undergoes metabolism by the N-acetyltransferase 2 (NAT2) enzyme.
Collins, Kimberly S., Raviele, Anthony L.J., Elchynski, Amanda L., Woodcock, Alexander M., Zhao, Yang, Cooper-DeHoff, Rhonda M., Eadon, Michael T.   +6 more
openaire   +3 more sources

Hydralazine inhibits ventricular tachyarrhythmias in an acquired long QT rabbit model

Journal of Arrhythmia, 2014
Background: Some cardioactive vasodilating agents inhibit ventricular tachyarrhythmias (VT) associated with acquired long QT syndrome (LQT). We tested whether a vasodilator without direct cardiac effect can eliminate abnormal repolarization-related VT ...
Kenta Tsutsui, MD, Satoshi Yamagishi, MD, Tomoyuki Kunishima, MD, Noriyuki Hayami, MD, Yuji Murakawa, MD   +4 more
doaj   +1 more source

Advances in Mechanochemical Methods for One‐Pot Multistep Organic Synthesis

Chemistry – A European Journal, EarlyView.
This review highlights recent advances in mechanochemical methods for multistep organic synthesis, focusing on sequential one‐pot approaches performed by grinding or ball milling. The presented transformations are discussed in terms of efficiency, applicability, and sustainability, assessing both the challenges and potential of solvent‐free one‐pot ...
Nina Biedermann, Michael Schnürch
wiley   +1 more source

Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody

Case Reports in Rheumatology, 2017
Drug induced lupus erythematosus (DIL or DILE) is an autoimmune disorder caused by chronic use of certain drugs. We report a unique case of hydralazine induced lupus syndrome (HILS) with a negative antinuclear antibody in a female patient who was on ...
Praneet Iyer, Ahmed Dirweesh, Ritika Zijoo   +2 more
doaj   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

A review on the clinical pharmacokinetics of hydralazine

Expert Opinion on Drug Metabolism & Toxicology, 2022
Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. The current article reviews the clinical pharmacokinetics (PK) of hydralazine, which can be useful for clinicians in optimizing its dose and dosing frequency to avoid adverse effects and unexpected interactions that could risk patients’ lives.
Asma, Shahzad Qamar, Ammara, Zamir, Sundus, Khalid, Waseem, Ashraf, Imran, Imran, Iltaf, Hussain, Anees Ur, Rehman, Hamid, Saeed, Abdul, Majeed, Faleh, Alqahtani, Muhammad Fawad, Rasool   +10 more
openaire   +2 more sources